Stock listing
OTC:BRSYF BrainsWay Ltd Stock
US listing (OTC) of BrainsWay Ltd · home listing TASE:BWAY
Follow BrainsWay Ltd into a list and get an email when it puts out news.
Share price · OTC:BRSYF
$10.62 USD -0.28 (-2.6%)
Close on Nov 11, 2026
- Day range
- $10.62 – $10.62 USDNov 11, 2026
- Volume
- 100 sharesNov 11, 2026
- Market cap
- $427.5M USDAt the close on Nov 11, 2026 · price × 40.25M shares outstanding
- 52-week range
- $8.00 – $16.84 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
- Traded on an average day
- $542 USDMedian day 0 shares · 55 days with no trades · last 3 months, Aug 11, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:BWAY · Home | 2,969.00 ILA (agorot) | -42.00 (-1.4%) | 138,643 | 3,024.00 | 3,024.00 | 2,864.00 | 3,011.00 | Close on Nov 19, 2026 |
| NASDAQ:BWAY | $8.48 USD | -0.25 (-2.9%) | 108,290 | $8.73 | $8.96 | $8.45 | $8.73 | Close on Nov 20, 2026 |
| OTC:BRSYF | $10.62 USD | -0.28 (-2.6%) | 100 | $10.62 | $10.62 | $10.62 | $10.90 | Close on Nov 11, 2026 |
Daily closes
Last 3 months, Aug 11, 2026 – Nov 6, 2026 · OTC:BRSYF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.77 | 0.00 | 0.0% | $11.77 | $11.77 | $11.77 | 0 | |
| $11.77 | 0.00 | 0.0% | $11.77 | $11.77 | $11.77 | 0 | |
| $11.77 | 0.00 | 0.0% | $11.77 | $11.77 | $11.77 | 0 | |
| $11.77 | 0.00 | 0.0% | $11.77 | $11.77 | $11.77 | 0 | |
| $11.77 | 0.00 | 0.0% | $11.77 | $11.77 | $11.77 | 0 | |
| $11.77 | +0.77 | +7.0% | $12.55 | $12.55 | $11.77 | 400 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | -1.60 | -12.7% | $11.00 | $11.00 | $11.00 | 500 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | 0.00 | 0.0% | $12.60 | $12.60 | $12.60 | 0 | |
| $12.60 | -2.53 | -16.7% | $12.60 | $12.60 | $12.60 | 100 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 300 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 300 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 300 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 300 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 300 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 | |
| $15.13 | 0.00 | 0.0% | $15.13 | $15.13 | $15.13 | 0 |
- Ticker
- OTC:BRSYF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Aug 27, 2026
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Latest earnings call · Nov 10, 2026
BrainsWay (TASE:BWAY) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Investor Presentation (November 2026)
Investor deck · 20 slides
Latest news
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Aug 27, 2026
Closed $15.13 (0.0%) on Aug 27, 2026
BrainsWay Announces Minority-Stake Investment in Hopemark Health
May 18, 2026
Closed $16.84 (0.0%) on May 18, 2026
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
Apr 29, 2026
Closed $13.55 (0.0%) on Apr 29, 2026
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
Apr 13, 2026
Closed $13.55 (0.0%) on Apr 13, 2026
Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants
Mar 30, 2026
Closed $11.87 (0.0%) on Mar 30, 2026
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
Mar 26, 2026
Closed $11.87 (0.0%) on Mar 26, 2026
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
Mar 19, 2026
Closed $11.87 (0.0%) on Mar 19, 2026
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Mar 11, 2026
Closed $11.87 (0.0%) on Mar 11, 2026
Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
Mar 4, 2026
Closed $11.87 (0.0%) on Mar 4, 2026
BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
Feb 25, 2026
Closed $11.54 (0.0%) on Feb 25, 2026
BrainsWay Ltd on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 19 in the last 12 months · 40 in all · newest Aug 27, 2026 · oldest 2025
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 10, 2026
- Decks
- 12 decks · latest Nov 10, 2026
Where BrainsWay Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:BWAY · Home listing | TASE | Israel | ILA |
| NASDAQ:BWAY | NASDAQ | United States | USD |
| OTC:BRSYF · This page | OTC | United States | USD |
| BOATS:BWAY | BOATS | United States | USD |
Valuation
P/E 35.0× against a median of 21.6×: 7th lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 19, 2026
- Enterprise value
- 1.00B ILS
- P/E
- 35.0×
- EV/sales
- 4.3×
- EV/EBITDA
- 26.8×
- Price/book
- 4.3×
- Gross margin
- 76.0%
- Operating margin
- 13.3%
- Net margin
- 14.6%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BrainsWay Ltd · TASE:BWAY | US$356.2M | US$299.1M | 35.0× | 4.3× | 26.8× | 4.3× | 14.6% | 0.1× | n/a |
| Ningbo Tianyi Medical Appliance Co., Ltd. Class A · SZSE:301097 | US$379.5M | US$354.5M | 309× | 3.3× | n/a | 2.4× | 1.1% | 0.4× | n/a |
| Chison Medical Technologies Co. Ltd. Class A · SSE:688358 | US$376.7M | US$224.1M | 21.6× | 3.3× | n/a | 1.9× | 25.5% | 0.0× | n/a |
| PolyNovo Limited · ASX:PNV | US$370.4M | US$358.6M | 76.2× | 3.8× | 38.9× | 6.2× | 5.1% | 0.2× | n/a |
| Taidoc Technology Corporation · TWSE:4736 | US$367.6M | US$206.4M | 4.7× | 1.6× | 7.4× | 1.1× | 60.7% | 0.1× | n/a |
| Star Sports Medicine Co., Ltd Class H · HKEX:1609 | US$347.2M | US$183.4M | 16.9× | 3.0× | 6.8× | 1.8× | 34.0% | 0.0× | n/a |
| Embecta Corp. · NASDAQ:EMBC | US$341.1M | US$1.58B | 3.9× | 1.6× | n/a | n/a | 8.6% | n/a | 0.74 |
| COLTENE Holding AG · SIX:CLTN | US$336.6M | US$376.3M | 18.9× | 1.3× | 11.4× | 3.0× | 6.2% | 0.6× | n/a |
| Jiangsu Canopus Wisdom Medical Technology Co., Ltd. Class A · SZSE:301290 | US$330.8M | US$220.5M | 29.6× | 3.4× | n/a | 1.0× | 17.2% | 0.1× | n/a |
| ACRO Biomedical Co., Ltd. · TPEX:6748 | US$327.3M | US$299.5M | n/a | 258× | n/a | 10.1× | −216.1% | 0.0× | n/a |
| Medcaptain Medical Technology Co. Ltd. Class H · HKEX:2041 | US$325.9M | US$288.8M | 44.4× | 1.2× | 9.7× | 1.1× | 3.0% | 0.1× | n/a |
| Median of the others | US$344.2M | US$294.1M | 21.6× | 3.2× | 9.7× | 1.9× | 7.4% | 0.1× | 0.74 |
Forecasts
Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.40 ILA · Analysts' mean
- Revenue, year to Dec 2026
- 69.78M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hadar Levy | Chief Executive Officer (CEO) |
| Ido Marom | Chief Financial Officer (CFO) |
| Menachem C. Klein | VP, General Counsel and Corporate Secretary |
| Colleen Hanlon | Vice President of Medical Affairs |
| Dor Hagai | Vice President of Operations |
| Moria Ben Soussan | Vice President of Research & Development |
| Nurit Tsur Lev | VP Commercial & Business Development |
| Gilead Moiseyev | Chief Technology Officer |
| Michael Cohen | Vice President of US Sales |
| Naomi Rozenfeld | Chief Marketing Officer |
| Yiftach Roth | Chief Scientific Officer (CSO) |
Board
| Director | Role |
|---|---|
| Ami Boehm | Board Chairman |
| Abraham Zangen | Board Director |
| Avner Hagai | Board Director |
| Avner Lushi | Board Director |
| David Feifel | Board Director |
| David Zacut | Board Director |
| Eti Mitrany | Board Director |
| Karen Sarid | Board Director |
| Mark Hallett | Board Director |
| Mark S. George | Board Director |
| Markus Heilig | Board Director |
| Zafiris 'Jeff' Daskalakis | Board Director |
Events
- Next results
- Mar 10, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| BrainsWay (TASE:BWAY) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q4 2025 Earnings Call | Wed, Mar 11, 2026 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q3 2025 Earnings Call | Tue, Nov 11, 2025 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q4 2024 Earnings Call | Tue, Mar 11, 2025 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 8:30 AM ET | Replay |
| BrainsWay (TASE:BWAY) Q1 2024 Earnings Call | Wed, May 08, 2024 · 8:00 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −4.7% |
| Q1 2025 | May 13, 2025 · Before open | +8.1% |
| Q4 2024 | Mar 11, 2025 · Before open | +3.6% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.5% |
| Q2 2024 | Aug 6, 2024 · Before open | +8.8% |
| Q1 2024 | May 8, 2024 · Before open | −0.7% |
| Q4 2023 | Mar 6, 2024 · After close | −7.1% |
| Q3 2023 | Nov 15, 2023 · Before open | +3.8% |
| Q2 2023 | Aug 9, 2023 · Before open | +4.6% |
| Q1 2023 | May 17, 2023 · Before open | +5.1% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 15, 2023 · After close | +2.1% |
| Q3 2022 | Nov 16, 2022 · Before open | −30.1% |
| Q2 2022 | Aug 10, 2022 · Before open | −11.3% |
| Q1 2022 | May 11, 2022 · Before open | +2.8% |
| Q4 2021 | Mar 9, 2022 · After close | −3.4% |
| Quarter to Sep 30, 2021 | Nov 17, 2021 · Before open | −2.3% |
| Quarter to Jun 30, 2021 | Aug 11, 2021 · Before open | +0.5% |
| Quarter to Mar 31, 2021 | May 20, 2021 · Before open | +1.4% |
| Quarter to Dec 31, 2020 | Mar 25, 2021 · After close | +6.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 20 slides | Nov 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 18 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 37 slides | May 13, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 36 slides | Mar 11, 2026 |
| Investor Presentation (November 2025) | Investor deck | 37 slides | Nov 12, 2025 |
| Investor Presentation (August 2025) | Investor deck | 34 slides | Aug 13, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 29 slides | May 13, 2025 |
| Investor Presentation (December 2018) | Investor deck | 27 slides | December 2018 |
| Investor Presentation (October 2018) | Investor deck | 22 slides | October 2018 |
| Investor Presentation (November 2017) | Investor deck | 22 slides | November 2017 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2016) | Investor deck | 33 slides | 2016 |
| Investor Presentation (July 2015) | Investor deck | 27 slides | July 2015 |
IPO
Priced at US$11.00 an ADS on Apr 16, 2019.
- Price
- US$11.00 an ADS
- ADSs offered
- 2,500,000 American depositary shares
- Offering size
- US$27.5 million
- Underwriters' option
- Up to 375,000 more ADSs
- Listing
- BWAY on the Nasdaq Global Market
- Underwriters
- Cantor, Raymond James, Oppenheimer & Co., Ladenburg Thalmann · In the order on the cover
- ADSs delivered
- On or about Apr 22, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 16, 2018 |
| Filed publicly | Jan 14, 2019 |
| Amended 3 times | Newest Apr 10, 2019 |
| Shares registered with an exchange | Apr 11, 2019 |
| Declared effective by the SEC | Apr 16, 2019 |
| Final prospectus, with the price | Apr 17, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 17, 2019 |
| EFFECT · Notice that a registration is effective | Apr 16, 2019 |
| CERT · Exchange's certificate of listing | Apr 15, 2019 |
| CORRESP · Letter to the SEC | Apr 12, 2019 |
| CORRESP · Letter to the SEC | Apr 12, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 11, 2019 |
| F-1/A · Registration statement, amended | Apr 10, 2019 |
| FWP · Free writing prospectus | Apr 10, 2019 |
| F-1/A · Registration statement, amended | Apr 3, 2019 |
| CORRESP · Letter to the SEC | Mar 26, 2019 |
All 17 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Mar 26, 2019 |
| UPLOAD · Letter from the SEC | Jan 30, 2019 |
| F-1 · Registration statement | Jan 14, 2019 |
| DRSLTR · Letter to the SEC with a draft | Dec 21, 2018 |
| DRS/A · Draft registration statement, amended | Dec 21, 2018 |
| UPLOAD · Letter from the SEC | Dec 12, 2018 |
| DRS · Draft registration statement | Nov 16, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 17, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.5M | 41.0M | 31.8M | 27.2M | 29.7M | 22.1M | 23.1M | 16.4M | 11.1M | 11.5M |
| Cost of revenue | 13.9M | 10.4M | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M |
| Gross profit | 42.6M | 30.6M | 23.5M | 20.0M | 23.1M | 17.0M | 18.0M | 12.8M | 8.55M | 9.10M |
| Research and development | 10.4M | 7.19M | 6.67M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M |
| Selling, general and administrative | 6.53M | 14.2M | 5.32M | 6.85M | 5.78M | 16.0M | 4.39M | 8.23M | 7.47M | 5.74M |
| Operating income | 4.68M | 1.39M | -4.96M | -12.7M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M |
| Depreciation and amortization | 1.54M | 660.0K | 362.0K | 558.0K | 560.0K | 438.0K | 550.0K | 463.0K | 394.0K | 649.0K |
| EBITDA | 6.22M | 2.05M | -4.60M | -12.1M | -4.44M | -4.39M | -7.93M | -4.65M | -6.22M | -1.42M |
| Interest expense | 2.39M | 1.52M | 1.16M | 1.47M | -1.68M | 319.0K | 1.43M | 1.16M | 274.0K | 404.0K |
| Income before tax | 8.35M | 3.46M | -3.95M | -13.0M | -6.42M | -5.15M | -9.91M | -6.27M | -6.88M | -2.40M |
| Income tax | 83.3K | 538.0K | 251.0K | 315.0K | 43.0K | 237.0K | 422.0K | 209.0K | 169.0K | |
| Net income | 8.26M | 2.92M | -4.20M | -13.3M | -6.46M | -5.38M | -10.3M | -6.48M | -7.05M | -2.40M |
| Earnings per share, basic | 0.19 | 0.09 | -0.13 | -0.40 | -0.21 | -0.24 | -0.46 | -0.39 | -0.48 | -0.17 |
| Earnings per share, diluted | 0.05 | -0.13 | -0.40 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 68.0M | 69.3M | 10.5M | 47.6M | 16.9M | 17.0M | 21.7M | 8.97M | 14.5M | 9.17M |
| Short-term investments | 1.43M | 0 | 35.5M | 271.0K | 40.4M | 221.0K | 221.0K | 101.0K | 50.0K | 585.0K |
| Receivables | 4.11M | 4.60M | 3.78M | 4.84M | 6.33M | 5.58M | 5.51M | 3.97M | 2.93M | 2.91M |
| Inventory | 7.14M | 4.43M | 3.72M | 3.84M | 200.0K | 442.0K | 306.0K | 91.0K | 271.0K | 585.0K |
| Current assets | 84.9M | 79.7M | 55.5M | 58.1M | 65.4M | 24.3M | 28.8M | 13.5M | 17.9M | 13.1M |
| Property, plant and equipment | 5.35M | 9.33M | 4.35M | 4.25M | 2.94M | 7.11M | 6.82M | |||
| Total assets | 112.9M | 94.3M | 63.0M | 64.5M | 75.7M | 34.0M | 38.7M | 23.6M | 27.0M | 20.0M |
| Accounts payable | 2.43M | 5.93M | 5.26M | 4.49M | 4.79M | 3.77M | 3.38M | 3.46M | 1.63M | 810.0K |
| Current liabilities | 22.2M | 15.3M | 9.76M | 8.14M | 9.07M | 6.80M | 6.72M | 8.34M | 6.13M | 4.39M |
| Long-term debt | 0 | 2.08M | 2.73M | |||||||
| Total debt | 6.82M | 5.62M | 471.0K | 488.0K | 754.0K | 429.0K | 414.0K | 2.83M | 2.73M | 810.0K |
| Total liabilities | 34.7M | 32.0M | 21.4M | 19.1M | 18.4M | 14.4M | 14.5M | 16.6M | 14.3M | 9.68M |
| Shareholders' equity | 73.2M | 62.3M | 41.6M | 45.4M | 57.3M | 19.6M | 24.2M | 6.95M | 12.7M | 10.3M |
| Shares outstanding | 42.4M | 37.6M | 33.2M | 33.1M | 32.9M | 22.3M | 22.2M | 16.6M | 14.8M | 14.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 18.0M | 10.3M | 1.28M | -9.76M | 884.0K | -1.44M | -7.24M | -3.77M | -3.47M | -2.40M |
| Capital spending | -1.75M | -3.79M | -2.39M | -1.94M | -2.24M | -2.47M | -3.31M | -1.97M | -985.0K | -408.0K |
| Free cash flow | 16.3M | 6.50M | -1.10M | -7.82M | -1.35M | -3.91M | -10.6M | -5.75M | -4.45M | -2.81M |
| Cash from investing | -17.5M | 30.3M | -37.4M | 42.2M | -42.2M | -2.46M | -2.45M | -1.14M | -2.45M | -393.0K |
| Cash from financing | -2.21M | 18.3M | -1.03M | -1.55M | 41.5M | -1.03M | 22.5M | -265.0K | 11.1M | 570.0K |
| Share buybacks | 0 | 0 | -52.0K | 0 | ||||||
| Change in cash | -1.65M | 58.8M | -37.1M | 30.7M | -40.0K | -4.71M | 12.7M | -5.54M | 5.33M | -2.18M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 8, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 283 filings. Open Filings
Cap table
Built by 6ix from BrainsWay Ltd’s releases
- Common shares
- 40,252,989
- Fully diluted
- 40,252,989
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 40,252,989 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 40,252,989 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amiram Boehm Other companies: Gilat Satellite Networks Ltd. (Director · Since at least Mar 17, 2026) | Director · Since at least Mar 18, 2026 |
| Avner Lushi Other companies: Silexion Therapeutics Corp (Director · Since at least Aug 15, 2024) | Director · Since at least Mar 18, 2026 |
| Hadar Levy Other companies: Lifeward Ltd. (Director · Since at least Aug 1, 2025) | Chief Executive Officer (CEO) · Since at least Mar 18, 2026 |
| Jonathan K Shulkin Other companies: SolarCity (Director · Mar 20, 2014 – Feb 23, 2015 · Past) | Director · Since at least Mar 18, 2026 |
| Abraham Zangen | Board Director · Since at least Mar 18, 2026 |
| Ami Boehm | Board Chairman · Since at least Nov 6, 2026 |
| Avner Hagai | Board Director · Since at least Nov 6, 2026 |
| Colleen Hanlon | Vice President of Medical Affairs · Since at least Mar 4, 2026 |
| David Feifel | Board Director · Since at least Nov 6, 2026 |
| David Zacut | Board Director · Since at least Mar 18, 2026 |
All 27 people
| Person | Seat |
|---|---|
| Dor Hagai | Vice President of Operations · Since at least Nov 6, 2026 |
| Eti Mitrany | Board Director · Since at least Nov 6, 2026 |
| Gilad Moiseyev | Chief Technology Officer · Since at least Mar 18, 2026 |
| Gilead Moiseyev | Chief Technology Officer · Since at least Nov 6, 2026 |
| Ido Marom | Chief Financial Officer (CFO) · Since at least Mar 18, 2026 |
| Karen Sarid | Board Director · Since at least Mar 18, 2026 |
| Mark Hallett | Board Director · Since at least Nov 6, 2026 |
| Mark S. George | Board Director · Since at least Nov 6, 2026 |
| Markus Heilig | Board Director · Since at least Nov 6, 2026 |
| Menachem C. Klein | VP, General Counsel and Corporate Secretary · Since at least Nov 6, 2026 |
| Michael Cohen | Vice President of US Sales · Since at least Feb 18, 2026 |
| Moria Ben Soussan | Vice President of Research & Development · Since at least Nov 6, 2026 |
| Naomi Rozenfeld | Chief Marketing Officer · Since at least Mar 18, 2026 |
| Nurit Tsur Lev | VP Commercial & Business Development · Since at least Nov 6, 2026 |
| Rayten Michal Ety Mitrany | Director · Since at least Mar 18, 2026 |
| Yiftach Roth | Chief Scientific Officer (CSO) · Since at least Mar 18, 2026 |
| Zafiris 'Jeff' Daskalakis | Board Director · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about BrainsWay Ltd.